FOLH1 and Familial prostate cancer: Furthermore, Lu-177 labelled urea-based peptide inhibitors of the prostate-specific membrane antigen (PSMA) have recently transformed prostate cancer treatment by delivering cytotoxic payloads systematically to all metastasis sites [34].